Practice Guideline
2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran): A Report of the American College of Cardiology Foundation Foundation/American Heart Association Task Force on Practice Guidelines

https://doi.org/10.1016/j.jacc.2011.01.010Get rights and content
Under an Elsevier user license
open archive

Key Words

AHA Scientific Statements
antithrombotic agents
atrial fibrillation
dabigatran
focused update

Cited by (0)

This document was approved by the American College of Cardiology Foundation Board of Trustees, the American Heart Association Science Advisory and Coordinating Committee, and the Heart Rhythm Society in January 2011.

The American College of Cardiology Foundation requests that this document be cited as follows: Wann LS, Curtis AB, Ellenbogen KA, Estes NAM 3rd, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, writing on behalf of the 2006 ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation Writing Committee. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011;57:1330–7.

This article is copublished in Circulation and HeartRhythm.

Copies: This document is available on the World Wide Web sites of the American College of Cardiology (www.cardiosource.org), the American Heart Association (my.americanheart.org), and the Heart Rhythm Society (www.hrsonline.org). For copies of this document, please contact Elsevier Inc. Reprint Department, fax (212) 633-3820, e-mail [email protected].

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American College of Cardiology Foundation. Please contact Elsevier's permission department at [email protected].

ACCF/AHA Representative.

HRS Representative.

ACCF/AHA Task Force on Performance Measures Representative.

§

Recused from voting on Section 8.1.4.2.5, Recommendation for Use of Oral Direct Thrombin Inhibitor Anticoagulant Agents.

ACCF/AHA Task Force on Practice Guidelines Liaison.